This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

Patients who received Vyvgart Hytrulo experienced a longer time to clinical deterioration compared with those who received placebo. The Food and Drug Administration (FDA) has approved Vyvgart ® ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...